Moleculin Biotech Files 8-K
Ticker: MBRX · Form: 8-K · Filed: Jul 30, 2025 · CIK: 1659617
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
Moleculin Biotech filed a routine 8-K. No major news.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on July 30, 2025, reporting on financial statements and exhibits. The filing does not appear to contain new material events or disclosures beyond standard reporting requirements.
Why It Matters
This filing indicates standard corporate reporting by Moleculin Biotech, Inc. It does not appear to contain significant new information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, indicating no immediate material changes or risks.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- July 30, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 47-4671997 (ein) — I.R.S. Employer Identification No.
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Principal executive offices
- 713-300-5160 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of July 30, 2025.
What is the exact name of the reporting company?
The exact name of the reporting company is Moleculin Biotech, Inc.
In which state was Moleculin Biotech, Inc. incorporated?
Moleculin Biotech, Inc. was incorporated in Delaware.
What is the principal executive office address for Moleculin Biotech, Inc.?
The principal executive office address is 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is July 30, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 30, 2025 regarding Moleculin Biotech, Inc. (MBRX).